erythromycin has been researched along with fleroxacin in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (20.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 5 (33.33) | 29.6817 |
| 2010's | 4 (26.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jolivette, LJ; Ward, KW | 1 |
| Jolivette, LJ; Nagilla, R; Ward, KW | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Du-Cuny, L; Mash, EA; Meuillet, EJ; Moses, S; Powis, G; Song, Z; Zhang, S | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Annand, R; Gozalbes, R; Jacewicz, M; Pineda-Lucena, A; Tsaioun, K | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Bale, MJ; Erwin, ME; Gerlach, EH; Jones, RN; Koontz, FP; Murray, PR; Washington, JA | 1 |
| Edelstein, MA; Edelstein, PH | 1 |
| Brunham, RC; Le Saux, NM; Plummer, FA; Ronald, AR; Slaney, LA | 1 |
| Pohlod, DJ; Saravolatz, LD; Somerville, MM | 1 |
| Meier-Ewert, H; Steele-Mortimer, O | 1 |
| Agneter, E; Burgdorff, T; Eichler, HG; Georgopoulos, A; Haag, O; Jansen, B; Müller, M; Pehamberger, H; Stanek, G; Weninger, W | 1 |
1 trial(s) available for erythromycin and fleroxacin
| Article | Year |
|---|---|
Characterization of peripheral-compartment kinetics of antibiotics by in vivo microdialysis in humans.
Topics: Adipose Tissue; Adult; Anti-Bacterial Agents; Anti-Infective Agents; Cefotaxime; Cefpirome; Cellulitis; Cephalosporins; Erythromycin; Female; Fleroxacin; Humans; Macrolides; Male; Microdialysis; Muscle, Skeletal; Skin | 1996 |
14 other study(ies) available for erythromycin and fleroxacin
| Article | Year |
|---|---|
Extrapolation of human pharmacokinetic parameters from rat, dog, and monkey data: Molecular properties associated with extrapolative success or failure.
Topics: Algorithms; Animals; Dogs; Haplorhini; Humans; Pharmaceutical Preparations; Pharmacokinetics; Rats; Species Specificity; Tissue Distribution | 2005 |
Comparative evaluation of oral systemic exposure of 56 xenobiotics in rat, dog, monkey and human.
Topics: Administration, Oral; Animals; Area Under Curve; Dogs; Haplorhini; Humans; Models, Statistical; Rats; Software; Species Specificity; Xenobiotics | 2005 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Computational modeling of novel inhibitors targeting the Akt pleckstrin homology domain.
Topics: Antineoplastic Agents; Blood Proteins; Caco-2 Cells; Cell Membrane Permeability; Computer Simulation; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Phosphoproteins; Protein Binding; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-akt; Quantitative Structure-Activity Relationship | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based permeability model for drug-like compounds.
Topics: Caco-2 Cells; Cell Membrane Permeability; Drug Discovery; Humans; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2011 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
MIC quality control guidelines for Haemophilus susceptibility tests using cefdinir (FK482), cefepime, cefetamet, cefpirome, ceftibuten, fleroxacin, temafloxacin, clarithromycin, RP59500, and trospectomycin.
Topics: Anti-Bacterial Agents; Cefdinir; Cefpirome; Ceftibuten; Ceftizoxime; Cephalosporins; Clarithromycin; Erythromycin; Fleroxacin; Fluoroquinolones; Haemophilus; Humans; Microbial Sensitivity Tests; Quality Control; Quinolones; Spectinomycin; Virginiamycin | 1992 |
In vitro activity of Ro 23-9424 against clinical isolates of Legionella species.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Colony Count, Microbial; Culture Media; Erythromycin; Extracellular Space; Fleroxacin; Fluoroquinolones; Guinea Pigs; Intracellular Fluid; Legionella; Macrophages, Alveolar; Microbial Sensitivity Tests | 1992 |
In vitro activity of ceftriaxone, cefetamet (Ro 15-8074), ceftetrame (Ro 19-5247; T-2588), and fleroxacin (Ro 23-6240; AM-833) versus Neisseria gonorrhoeae and Haemophilus ducreyi.
Topics: Cefmenoxime; Ceftizoxime; Ceftriaxone; Cephalosporins; Ciprofloxacin; Erythromycin; Fleroxacin; Haemophilus ducreyi; Humans; Neisseria gonorrhoeae; Penicillins; Spectinomycin; Tetracycline | 1987 |
Inhibition of Legionella pneumophila multiplication within human macrophages by fleroxacin.
Topics: Anti-Infective Agents; Cefoxitin; Ciprofloxacin; Erythromycin; Fleroxacin; Humans; Legionella; Macrophages; Microbial Sensitivity Tests; Rifampin | 1988 |
In-vitro activity of fleroxacin against Chlamydia trachomatis.
Topics: Anti-Infective Agents; Chlamydia trachomatis; Ciprofloxacin; Clindamycin; Drug Resistance, Microbial; Erythromycin; Fleroxacin; Microbial Sensitivity Tests; Tetracyclines | 1988 |